Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.60 |
| ▸ | KMO | O15229 | 8/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953950 | 0.85 | TMEM97 (0.56) | TMEM97KMOSIGMAR1NPY5RCYP3A4 | |
| SCHEMBL3224688 | 0.83 | HTT (0.65) | HTTL3MBTL1TMEM97KMO | |
| SCHEMBL3221281 | 0.82 | TMEM97 (0.53) | HTTL3MBTL1TMEM97SIGMAR1NPY5R | |
| SCHEMBL8870033 | 0.79 | TMEM97 (0.67) | L3MBTL1TMEM97SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL11193880 | 0.79 | TMEM97 (0.56) | TMEM97SIGMAR1NPY5RCYP3A4CYP2D6 | |
| SCHEMBL11343567 | 0.79 | TMEM97 (0.56) | TMEM97SIGMAR1NPY5RCYP3A4CYP2D6 | |
| SCHEMBL7822750 | 0.79 | HTT (1.00) | HTTL3MBTL1CYP3A4CYP2D6 | |
| SCHEMBL18271816 | 0.79 | HTT (0.56) | HTTL3MBTL1TMEM97KMO | |
| SCHEMBL11343563 | 0.78 | TMEM97 (0.54) | TMEM97SIGMAR1NPY5RCYP3A4CYP2D6 | |
| SCHEMBL8870438 | 0.78 | TMEM97 (0.66) | L3MBTL1TMEM97SIGMAR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298010-A1 | 3-(5-CHLORO-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-3-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016188828-A1 | 3-(5-CHLORO-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-3-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-01 | — | — | WO | disclosed |
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-1997043282-A2 | BENZOTHIAZOLINONES AS ANTI-ASTHMATIC AGENTS | KLINGE PHARMA GMBH (DE) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | HTT 2154/4885L3MBTL1 1539/4885TMEM97 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.